Prostate Cancer
Show Only Open Trials
1.
GO27983: A Phase Ib/II Study of GDC-0068 or GDC-0980 with Abiraterone Acetate versus Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy
- Study Status: Open to Enrollment
- Sponsor: Genentech
- Disease Status and/or Stage: Metastatic or Advanced Prostate Cancer
- Protocol ID: GO27983
2.
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy
- Study Status: Open to Enrollment
- Sponsor: Amgen
- Disease Status and/or Stage: Prostate Cancer Receiving Androgen Deprivation Therapy
3.
A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects with Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Study Status: Open to Enrollment
- Sponsor: PSMA Development Company
- Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
- Protocol ID: PSMA ADC 2301
4.
S1216: Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: SWOG
- Disease Status and/or Stage: Metastatic Prostate Cancer
- Protocol ID: S1216
5.
A Phase 1a/b Non-Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile Compound 31510 (Ubidecarenone, USP) Nanosuspension for Injection Administered Intravenously to Patients with Solid Tumors
- Study Status: Open to Enrollment
- Sponsor: Berg Pharma
- Disease Status and/or Stage: Advanced Solid Tumors
6.
7.
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100
- Study Status: Open to Enrollment
- Sponsor: Exelixis
- Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
- Protocol ID: XL184-307
8.
A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
9.
Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Metastatic Epithelial Cancer
10.
CALGB 70807: The Men's Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance
- Study Status: Open to Enrollment
- Sponsor: CALGB
11.
A Phase 1b Safety Study of Abiraterone Acetate (JNJ 212082) and Docetaxel in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (COU-AA-206)
- Study Status: Open to Enrollment
- Sponsor: Cougar Biotechnology
- Disease Status and/or Stage: Metastatic Castration-Resistant Prostate Cancer
12.
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B, National Cancer Institute
- Disease Status and/or Stage: High Risk, Clinically Localized Prostate Cancer
- Protocol ID: CALGB 90203
13.
Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer using 177Lu-J591 Antibody: Dose Fractionation Regimen
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Prostate Cancer
14.
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Relapsed Prostate Cancer
15.
A Phase I Trial of Docetaxel/Prednisone plus Fractionated 177Lu-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients with Metastatic, Castrate-Resistant Prostate Cancer
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Prostate Cancer
16.
A Phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy
- Study Status: Open to Enrollment
- Sponsor: Radiation Therapy Oncology Group, National Cancer Institute
- Disease Status and/or Stage: Prostate Cancer After Radical Prostatectomy
